<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475549</url>
  </required_header>
  <id_info>
    <org_study_id>C6463-201</org_study_id>
    <nct_id>NCT04475549</nct_id>
  </id_info>
  <brief_title>Phase 2a Study of IW-6463 in Adults Diagnosed With MELAS</brief_title>
  <official_title>A Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Individuals With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclerion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cyclerion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults
      diagnosed with MELAS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single-arm study with daily dosing for up to 29 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number (or %) of participants who discontinue or dose reduced the study drug due to a treatment-emergent adverse event (TEAE)</measure>
    <time_frame>From first dose date to Day 43 (±4)</time_frame>
    <description>TEAE is defined as an adverse event with an onset that occurs after receiving the study drug, until the end of study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number (or %) of participants who experience at least one treatment-emergent adverse event (TEAE)</measure>
    <time_frame>From first dose date to Day 43 (±4)</time_frame>
    <description>TEAE is defined as an adverse event with an onset that occurs after receiving the study drug, until the end of study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number (or %) of participants who experience at least one treatment-emergent adverse event (TEAE) by severity</measure>
    <time_frame>From first dose date to Day 43 (±4)</time_frame>
    <description>TEAE is defined as an adverse event with an onset that occurs after receiving the study drug, until the end of study period</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>MELAS</condition>
  <arm_group>
    <arm_group_label>IW-6463</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-6463 Tablets</intervention_name>
    <description>IW-6463 tablets administered orally (daily)</description>
    <arm_group_label>IW-6463</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior genetic confirmation of a known mitochondrial disease mutation

          2. Neurological features of MELAS (can be based on medical history)

          3. Elevated plasma lactate levels at Screening Visit (&gt;2.0 mmol/L)

          4. Women of childbearing potential must have a negative pregnancy test prior to
             randomization and must agree to use protocol-specified contraception from the
             Screening Visit through 90 days after the final dose of study drug.

          5. Male participants must be surgically sterile by vasectomy (conducted ≥60 days before
             the Screening Visit or confirmed via sperm analysis) or must agree to use
             protocol-specified contraception and agree to refrain from sperm donation from the
             Screening Visit through 90 days after the final dose of study drug.

          6. Other inclusion criteria per protocol

        Exclusion Criteria:

          1. Positive pregnancy test at Screening or on Day 1

          2. Hypotension defined as systolic BP ≤90 mmHg or diastolic BP ≤60 mmHg at Screening or
             predose at Day 1

          3. Hypertension defined as systolic BP &gt;160 mmHg or diastolic BP &gt;100 mmHg, at Screening
             or predose at Day 1

          4. Uncontrolled diabetes

          5. Severe gastrointestinal dysmotility as determined by the investigator that may impact
             compliance and/or oral drug administration, absorption and exposure.

          6. Unable to fast for 3-4 hours after a meal

          7. Unable or unwilling to adhere to the study schedule, lifestyle restrictions,
             assessment requirements or, in the clinical judgment of the investigator, is otherwise
             not suitable for study participation.

          8. Current or past history of clinically significant cardiomyopathy and/or cardiac
             conduction abnormality

          9. Used any nicotine-containing products (eg, cigarettes, e-cigarettes, vape pens,
             cigars) within 1 month of enrollment

         10. Other exclusion criteria per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Glasser, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Cyclerion Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Miller</last_name>
    <phone>+1 857 338 3355</phone>
    <email>PMiller@cyclerion.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitochondrial disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MELAS Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

